Envoy Medical’s (COCH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Envoy Medical (NASDAQ:COCH) in a report published on Wednesday,Benzinga reports. They currently have a $2.50 price target on the stock. HC Wainwright also issued estimates for Envoy Medical’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.19) EPS.

COCH has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a research note on Friday, April 24th. Zacks Research raised Envoy Medical to a “hold” rating in a research note on Wednesday, April 1st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.50.

Envoy Medical Price Performance

Envoy Medical stock opened at $0.70 on Wednesday. The firm has a 50 day simple moving average of $0.69 and a 200-day simple moving average of $0.68. The stock has a market capitalization of $53.94 million, a PE ratio of -0.69 and a beta of 1.88. Envoy Medical has a 12-month low of $0.36 and a 12-month high of $1.89.

Envoy Medical (NASDAQ:COCH) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. On average, analysts forecast that Envoy Medical will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of Envoy Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in Envoy Medical by 111.3% in the fourth quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after buying an additional 51,813 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Envoy Medical in the third quarter valued at $60,000. Focus Partners Wealth bought a new position in shares of Envoy Medical in the first quarter valued at $276,000. Finally, DSG Capital Advisors LLC acquired a new stake in shares of Envoy Medical during the 1st quarter valued at $416,000. 8.59% of the stock is currently owned by institutional investors.

More Envoy Medical News

Here are the key news stories impacting Envoy Medical this week:

• Negative Sentiment: HC Wainwright lowered its Q2 2026 EPS estimate for Envoy Medical to ($0.09) from ($0.08) and cut its Q3 2026 EPS estimate to ($0.07) from ($0.06), signaling slightly weaker profitability expectations. Article link
• Neutral Sentiment: The firm still kept a Buy rating and $2.50 price target on COCH, suggesting analysts remain constructive on the longer-term story despite the near-term estimate cuts. Article link
• Neutral Sentiment: HC Wainwright also slightly improved its FY2026 EPS forecast to ($0.29) from ($0.30) and projected FY2027 EPS of ($0.19), indicating losses are expected to narrow over time. Article link

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.